Analysis on Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) Medical Device Market with Clinical Trails Landscape in 2017


Published on : Jun 16, 2017

Albany, New York, June 16, 2017: Rising prevalence of cardiac disorders and rising incidences of heart failure are anticipated to boost the CRT market growth in the coming years. CRT devices are being primarily used to prevent the surgical cost and readmission rate in hospitals, thereby propelling its growth. To explore current scenario and evaluation of pipeline products, Market Research Hub (MRH) has recently announced the inclusion of a new study to its vast portfolio of research reports, which is titled as “Cardiac Resynchronisation Therapy- Defibrillators (CRT-D) - Medical Devices Pipeline Assessment, 2017”. This pipeline study mainly aims to provide comprehensive information on the pipeline products with the comparative analysis of the products at various stages of development.

At first, the reports starts be presenting the brief introduction of Cardiac resynchronization therapy along with, pipeline products analysis by stage of development, segment, territory, regulatory path and estimated approval date. Over the last 10 years, several large, well-designed clinical trials have firmly established the role of cardiac resynchronization therapy (CRT) as a recommended treatment strategy for moderate-to-severe heart failure (HF).

CRT is a clinically proven treatment option for some individuals with heart failure. These devices help in the proper synchronization of heart beats by directing small undetectable signals to lower chambers of the heart. This, in turn, enables the heart to pump blood and oxygen more efficiently. Cardiac Resynchronization Therapy (CRT) may be part of a permanent pacemaker or cardio-defibrillator system that can help to improve heart pump function in people with an enlarged, weakened heart and symptoms of heart failure. The two major types of implantable heart devices are cardiac resynchronization therapy (CRT) pacemaker and a CRT pacemaker with defibrillation therapy. These devices improve blood flow and coordinate the heart’s pumping action.

This study also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) pipeline products. The report offers key clinical trial data of ongoing trials specific to the given pipeline products. As of 2015, CRT-D is expected to dominate owing to their higher performance of pacing activity and ability to timely report adverse conditions, thereby limiting the death rate. However, key players are working toward further improvement.

Later on, the study reviews leading players involved in the development of Cardiac Resynchronisation Therapy - Defibrillators (CRT-D) along with their pipeline products and ongoing clinical trials overview. Currently, Boston Scientific Corp., John Hopkins University, IRadimed Corp, Mayo Clinic US, LivaNova PLC, Medtronic plc, Jude Medical, TransWorld Med Corp. and NewPace Ltd. are the leading players profiled in the study.

Click here to get more info with TOC in a PDF Formathttp://www.marketresearchhub.com/enquiry.php?type=S&repid=1135719

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-518-621-2074

+1-866-997-4948US Toll Free

Email : sales@marketresearchhub.com

Back To Top